ameliorate the progression of cardiac remodeling in vivo, possibly because of inhibition of the small GTPase Rac1. The role of Rac1 in mediating myocyte apoptosis is not known. ␤-Adrenergic receptor (␤AR)-stimulated myocyte apoptosis is mediated via activation of c-Jun NH 2 -terminal kinase (JNK), leading to activation of the mitochondrial death pathway. We hypothesized that ␤AR-stimulated apoptosis in adult rat ventricular myocyte (ARVMs) is mediated by Rac1 and inhibited by statins. Methods and Results-␤AR stimulation increased apoptosis, as assessed by transferase-mediated nick-end labeling, from 5Ϯ1% to 24Ϯ2%. ␤AR stimulation also increased Rac1 activity. Adenoviral overexpression of a dominant-negative mutant of Rac1 inhibited ␤AR-stimulated apoptosis, JNK activation, cytochrome C release, and caspase-3 activation. Cerivastatin likewise inhibited the ␤AR-stimulated activation of Rac1, decreased ␤AR-stimulated apoptosis to 11Ϯ2%, and inhibited JNK activation, cytochrome C release, and caspase-3 activation.
I nhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, or statins, appear to have beneficial effects on the myocardium that are independent of their ability to lower serum cholesterol. 1 This impression is supported by animal studies in which statins ameliorate the myocardial remodeling that occurs after myocardial infarction or pressure overload. [2] [3] [4] Moreover, in cardiac myocytes in vitro, statins inhibit the hypertrophic responses to several stimuli, including ␣-adrenergic receptor (␣AR) stimulation 3, 5 and angiotensin. 6 These effects have been attributed in part to inhibition of the synthesis of isoprenoid intermediates involved in the subcellular localization of small GTPases, including Rac1. 1 Rac1 has been shown to mediate hypertrophy in cardiac myocytes. Adenoviral-mediated overexpression of V12Rac1 results in a hypertrophic phenotype, whereas expression of the N17Rac1 dominant-negative mutant inhibits ␣AR-stimulated and strain-induced myocyte hypertrophy 7, 8 It has further been suggested that the anti-hypertrophic effect of statins is due to a decrease in the generation of reactive oxygen species (ROS), 3 which can act as signaling molecules for myocyte hypertrophy. 9, 10 We 11, 12 and others [13] [14] [15] have shown that ␤-adrenergic receptor (␤AR) stimulation of cardiac myocytes leads to apoptosis. Recently, we found that ␤AR-stimulated myocyte apoptosis is mediated via the ROS-dependent activation of c-Jun NH 2 -terminal kinase (JNK), leading to activation of the mitochondrial death pathway. 16 Because both Rac1 17, 18 and ROS 19 are upstream mediators of JNK activation in a variety of cell types, these observations raised the possibility that statins might inhibit ␤AR-stimulated myocyte apoptosis. On the other hand, prior studies have found that statins, albeit in relatively high concentrations, increase apoptosis in cardiac myocytes 20, 21 and vascular endothelial cells. 22 Accordingly, the goal of this study was to test whether a pharmacologically relevant concentration of a statin can inhibit ␤AR-stimulated apoptosis in adult rat ventricular myocytes (ARVMs) in primary culture and, if so, to determine the mechanism of this action.
Methods

Isolation and Treatment of ARVMs
ARVMs were prepared as previously described. 11, 12 ␤AR stimulation was accomplished by treating with L-norepinephrine (NE; 10 mol/L; Sigma) in the presence of prazosin (PZ; 0.1 mol/L; Sigma), 11, 12 and apoptosis was assessed after 24 hours, whereas caspase-3 activity and cytochrome C mobilization were assessed after 6 hours. Cerivastatin (0.005 mol/L; Bayer AG) was added 1 hour before NE. Simvastatin (0.05 mol/L; Calbiochem) was added 18 hours before NE. All dishes were supplemented with ascorbic acid (0.1 mmol/L). The N17 dominant-negative mutant of Rac1 7 (courtesy of T. Finkel, Bethesda, Md) or ␤-galactosidase was expressed using an adenoviral vector at a multiplicity of infection of 100. In some experiments, a voltage-dependent calcium channel antagonist (nifedipine; 5 mol/L; Sigma), Ca 2ϩ /calmodulin kinase II (CaMKII) inhibitor (KN93; 0.5 mol/L; Calbiochem), or protein kinase A inhibitor (PKI; 0.5 mol/L; Calbiochem) was added 2 hours before NE.
Myocyte Apoptosis
Apoptosis was assessed by terminal deoxynucleotidyl transferasemediated nick-end labeling (TUNEL) as previously described 11 using a Roche Molecular Biochemical kit according to the manufacturer's instructions. The percentage of TUNEL-positive myocytes, relative to total myocytes, was determined by counting, in a blinded manner, 400 to 500 cells in 20 randomly chosen fields per coverslip for each experiment. Nuclei were counterstained with Hoechst 33342 (10 g/mL for 10 minutes at room temperature).
Cytochrome C Release
Mitochondrial and cytosolic cytochrome C fractions, prepared as described by Gottlieb and Granville, 23 were assayed by Western blotting with an antibody to cytochrome C (Pharmingen).
Caspase-3 Activity
Caspase-3 activity was measured as previously described 24 in cell extracts using an EnzChek Caspase-3 Assay Kit No. 2 (Molecular Probes) and normalized for cell protein.
Akt Activity
Total cellular homogenates were prepared, and equal amounts (50 g) of the denatured proteins were loaded and separated on 10% or 12% SDS-PAGE (Mini Protean II; Biorad) and transferred to polyvinylidene difluoride membranes (Hybond-P; Amersham Life Science). The membrane was blocked with 4% BSA in TBS for 1 hour. Akt activity was determined by incubation with 1:200 rabbit polyclonal antibody to phospho-Akt kinase or total Akt (Cell Signaling) overnight in 4% BSA in TBS at 4°C. Membranes were washed three times with TBS, followed by incubation for 1 hour with a horseradish peroxidase-labeled goat anti-rabbit antibody (Santa Cruz) in 4% BSA in TBS. The membranes were exposed to a chemiluminescent reagent (Pierce) and autoradiographed for 1 to 2 minutes JNK Activity JNK activity was determined by immunoprecipitation of the active form with a c-Jun fusion protein in the presence of cold ATP using a SAPK/JNK Assay Kit (Cell Signaling). Precipitated JNK was resolved on 12% SDS-PAGE and detected by Western blotting using an anti-phospho-c-Jun antibody.
Rac1 Activity
Activated Rac1 was detected with an Rac Activation Assay Kit (Upstate Biotechnology, Inc) according to the manufacturer's instructions. Briefly, Rac activation was determined by measuring the fraction bound to a GST-PBD protein (p21-binding domain of human PAK-1) in a total cellular protein lysate. Precipitated GTP-bound Rac1 was resolved on 4% to 20% SDS-PAGE and detected by Western blotting with monoclonal antibodies specific for Rac1 (1:1000).
Statistical Analysis
All data are expressed as meanϮSEM. Differences across multiple conditions were tested by 1-way ANOVA for repeated measures. Comparisons between conditions were tested by the Student unpaired t test using the Bonferroni correction for multiple comparisons.
Results
␤AR-Stimulated Apoptosis Is Inhibited by Cerivastatin
␤AR stimulation with NE/PZ for 24 hours increased the percentage of TUNEL-positive cells from 5Ϯ1% to 24Ϯ2% (Figures 1 and 2 ). Addition of cerivastatin 1 hour before ␤AR stimulation decreased the percentage of TUNEL-positive cells to 11Ϯ2%. Pretreatment with a different statin, simvastatin (0.05 mol/L), likewise inhibited ␤AR-stimulated apoptosis by 72Ϯ17% (PϽ0.05 versus NE/PZ; nϭ5).
We previously found that ␤AR-stimulated apoptosis is associated with cytochrome C release into the cytosolic fraction and caspase-3 activation. 16 ␤AR stimulation increased cytosolic cytochrome C by 2.4Ϯ0.1-fold ( Figure 3A ). Pretreatment with cerivastatin inhibited ␤AR-stimulated cytochrome C release by 48Ϯ2%. ␤AR stimulation increased caspase-3 activity by 24Ϯ3%. Pretreatment with cerivastatin inhibited the ␤AR-stimulated increase in caspase-3 activity by 74Ϯ17%, reducing it to a 6% increase over baseline (PϽ0.05 versus NE/PZ; nϭ7).
␤AR-Stimulated JNK Activation Is Inhibited by Cerivastatin
We previously reported that ␤AR-stimulated apoptosis is mediated by JNK, which acts upstream of mitochondrial cytochrome C release 16 ␤AR stimulation (15 minutes) increased JNK activity by 4.0Ϯ0.9-fold, and this effect was inhibited 80Ϯ26% by cerivastatin (PϽ0.05 versus NE/PZ; nϭ5) ( Figure 3B ).
␤AR Stimulation Causes Statin-Sensitive Rac1 Activation
␤AR stimulation (7 minutes) increased Rac1 activation 4.9Ϯ1.0-fold, and this effect was inhibited 70Ϯ9% by cerivastatin ( Figure 4 ). However, ␤AR stimulation tended to increase Akt activity, which was not affected by cerivastatin (PϭNS; nϭ3).
Roles of Calcium and ROS in ␤AR-Stimulated Rac1 Activation
␤AR-stimulated Rac1 activation was inhibited 67Ϯ10% (PϽ0.05 versus NE/PZ; nϭ3) by the voltage-dependent calcium channel antagonist nifedipine, 55Ϯ14% by the protein kinase A inhibitor PKI ( Figure 5A ), and 51Ϯ11% ( Figure  5A ) by the CaMKII inhibitor KN93. Likewise, ␤ARstimulated apoptosis was inhibited 51Ϯ7% (Figure 5B ) by PKI and 43Ϯ19% by KN93 ( Figure 5B ). To examine the whether ␤AR-stimulated Rac1 activation is proximal or distal to ROS generation, ARVMs were infected with an adenoviral vector for catalase, as previously described. 16 Catalase overexpression had no effect on that ␤AR-stimulated Rac1 activation (PϭNS; nϭ3).
Role of Rac1 in ␤AR-Stimulated Apoptosis
To further examine the role of Rac1 in ␤AR-stimulated apoptosis, ARVMs were infected with an adenoviral vector expressing a dominant-negative mutant of Rac1 (N17 Rac1).
Control cells were infected with an adenoviral vector for lac-Z. Overexpression of lac-Z or dominant-negative Rac1 alone had no effect on apoptosis, whereas dominant-negative Rac1 inhibited ␤AR-stimulated apoptosis by 62Ϯ2% ( Figure  6A ). Overexpression of the Rac1 dominant-negative mutant likewise abolished ␤AR-stimulated cytochrome C release (Ϫ95Ϯ26%; PϽ0.05 versus NE/PZ/lac-Z; nϭ5), caspase-3 activation (Ϫ161Ϯ34%; PϽ0.05 versus NE/PZ/lac-Z; nϭ7), and JNK activation ( Figure 6B ). 
Discussion
We 11, 12 and others [13] [14] [15] have shown that ␤AR stimulation in cardiac myocytes results in apoptosis that is mediated by ROS-dependent activation of JNK and the mitochondrial death pathway. 16 This study demonstrates that ␤ARstimulated JNK activation and apoptosis in ARVMs require Rac1. We further show for the first time that statins inhibit ␤AR-stimulated JNK activation and apoptosis and that these effects are due to inhibition of ␤AR-stimulated Rac1 activation.
A new finding of this study is that ␤AR stimulation causes Rac1 activation. Furthermore, adenoviral overexpression of the N17Rac1 dominant-negative mutant inhibited ␤ARstimulated apoptosis and 3 known steps in the signaling pathway leading to ␤AR-stimulated apoptosis: JNK activation, cytochrome C release, and caspase-3 activation. Thus, in cardiac myocytes, ␤AR stimulation couples to Rac1 activation, which is upstream of JNK in the mitochondrial death pathway and necessary for ␤AR-stimulated apoptosis.
Little is known about the role of Rac1 in mediating apoptosis in cardiac myocytes. However, Rac1 may regulate JNK activity, 17, 18 and apoptosis in neuronal cells has been shown to involve Rac1-dependent activation of JNK. 25 In addition, Rac1 may be a source of ROS 3 that may participate in mediating either hypertrophy or apoptosis in cardiac myocytes. 19 We previously found that adenovirus-mediated overexpression of catalase inhibits ␤AR-stimulated JNK activation and apoptosis. 16 In the present study, we found that catalase overexpression has no effect on ␤AR-stimulated Rac1 activation, thus indicating that Rac1 is proximal to ␤AR-stimulated ROS generation. This conclusion is consistent with the suggestion that Rac1 participates in the generation of ROS. 3 Given the well-described role of Rac1 in mediating hypertrophy in cardiac myocytes, 7, 8 it will be of interest to understand the mechanism by which hypertrophic versus apoptotic stimuli (eg, ␣AR versus ␤AR stimulation) use Rac1 to yield distinct phenotypes. Of note, myocyte-specific overexpression of Rac1 in mice can result in either myocardial hypertrophy or a dilated cardiomyopathy. 26 Recently, it was shown that Rac1 activity is increased in myocardium obtained from patients with heart failure and is decreased in association with statin therapy, leading to the suggestion that Rac1 contributes to the pathophysiology of myocardial failure and may be a site of action for the beneficial effects of statins in the myocardium. 27 Our study suggests that the beneficial effects of statins on the myocardium are due, at least in part, to inhibition of Rac1-dependent myocyte apoptosis. This suggestion is supported by the demonstration that statin therapy prevents the development of heart failure and decreases myocyte apoptosis in Dahl rats and that this effect was associated with a decrease in the frequency of apoptotic myocytes. 28 Several studies have shown that statins inhibit myocyte hypertrophy in vitro or in vivo. [2] [3] [4] [5] [6] 29, 30 Very little is known about the effect of statins on cardiac myocyte apoptosis. However, at least 2 studies have suggested that statins can increase apoptosis in cardiac myocytes in vitro. 20, 21 To the contrary, we found that cerivastatin markedly inhibits ␤ARstimulated apoptosis. Serum levels of cerivastatin in humans are between 2 and 50 nmol/L. 31 We observed an antiapoptotic effect of cerivastatin at the clinically relevant concentration of 5 nmol/L, whereas the proapoptotic effects reported in prior studies were observed at much higher concentrations. 20, 21 In this regard, Weis et al 22 found that high concentrations of statin increase apoptosis in microvascular endothelial cells, whereas lower concentrations attenuate hypoxiainduced apoptosis. We have likewise noted a proapoptotic effect of cerivastatin at high concentrations.
We found that statins inhibit ␤AR-stimulated JNK activation, cytochrome C release, and caspase-3 activation, suggesting that they inhibit apoptosis by acting at or proximal to Rac1. Although we cannot exclude the possibility that the statins acted at a site proximal to Rac1, the ability of statins to inhibit Rac1 function by preventing geranylgeranylation is well described. 1 Another possible mechanism of the statin effect is via stimulation of the PI-3 kinase/Akt pathway, which can exert both hypertrophic and antiapoptotic effects in cardiac myocytes 32, 33 and has been implicated in mediating the effects of statins, in part through stimulation of nitric oxide synthase. 34 However, this mechanism does not appear to be involved in our system because statin did not cause Akt activation. Recently, it was shown that statins can inhibit oxidant-induced mitochondrial dysfunction via nitric oxidemediated activation of the ATP-sensitive potassium channel. 35 However, this effect occurred only at concentrations of Ն1 mol/L and therefore cannot account for the antiapoptotic effect we observed at much lower concentrations.
We 11 and others have found that calcium is involved in mediating ␤AR-stimulated apoptosis in ARVMs. Recently, Zhu et al 36 found that ␤AR-stimulated apoptosis in mouse myocytes involves calcium-dependent activation of CaMKII that is independent of protein kinase A. We found that the voltage-dependent calcium channel antagonist nifedipine and inhibitors of either PKA (PKI) or CaMKII (KN93) each caused a partial decrease in ␤AR-stimulated apoptosis, suggesting that under the conditions of our study, ␤ARstimulated Rac1 activation is calcium dependent and involves both protein kinase A and CaMKII. We have also found that inhibition of either the ␤ 1 -or ␤ 2 -AR subtype causes partial inhibition of ␤AR-stimulated Rac1 activation (data not shown), suggesting that both subtypes can couple to Rac1. Because in this system the ␤ 1 subtype couples to apoptosis whereas the ␤ 2 subtype exerts an antiapoptotic action, 12 our data are consistent with the thesis that the antiapoptotic action of the ␤ 2 subtype reflects coupling to an additional antiapoptotic pathway. 37 These results may have particular clinical relevance for conditions such as heart failure in which sympathetic stimulation of the myocardium is increased. It is unclear how the concentration of NE (10 mol/L) used in this study relates to the interstitial concentration in failing myocardium. However, in adult rat cardiac myocytes, as used in this study, the maximal contractile response to NE is not achieved until a concentration of Ϸ10 mol/L. 38 In addition, although under the conditions of these experiments (ie, quiescent cells) there is little or no apoptosis at NE concentrations Ͻ10 mol/L, we have found that the apoptotic threshold for NE is markedly lower (Ͻ0.1 mol/L) when the myocytes are paced at 5 Hz. 39 Statins have been shown to ameliorate remodeling and to improve survival in animals after myocardial infarction 2, 40 and after aortic constriction. 3, 4 Clinical trails have suggested that statins may exert beneficial effects on the clinical course of myocardial failure in patients with or without coronary artery disease. [41] [42] [43] These basic and clinical observations have led to the suggestion that statins may be of value in the prevention and treatment of myocardial failure. 3, 27, 44 Although most studies to date have focused on the antihypertrophic effect of statins in the myocardium, 2-6 our findings suggest that statins may exert a beneficial effect in failing myocardium, at least in part, by inhibition of Rac1-mediated myocyte apoptosis.
